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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 















ICL | preprint 
(not peer 
reviewed) 
• Using data from the Real-time 
Assessment of Community 
Transmission-1 (REACT-1) 
study in England to investigate 
symptom profiles for PCR 
positivity at different ages a 
wider range of symptoms 
beyond the ‘classic 4’ were 
associated with COVID-19 
• In addition to fever, loss of 
smell, loss of taste and new 
persistent cough, other 
symptoms – chills, loss of 
appetite, headache and 
muscle aches - either alone or 
in combination were 
associated with SARS-CoV-2 
infection 
• The more symptoms people 
showed the more likely they 
were to test positive 
• Also, there was variation in 
symptoms with age. Chills 
were linked with testing 
positive across all ages, 
headaches were reported in 
young people aged 5-17, 
appetite loss in 18-54 and 




people aged 18-54. Infected 
5-17 year olds were also less 
likely to report fever, 
persistent cough and appetite 
loss compared with adults 
• These new findings suggest 
that many people with COVID-
19 won’t be getting tested, 
and therefore self-isolating, 
and using this extended list of 
symptoms three-quarters of 
symptomatic infections could 
be detected, if everyone 
eligible were tested, up from 
around half of all symptomatic 
infections with the current list 
of 4 symptoms. 
• The research also explored 
whether the emergence of the 
UK’s new variant linked with a 
different profile of symptoms  
• While symptoms were broadly 
similar, loss of change to 
sense of smell was less 
predictive of having COVID-
19, while the proportion of 
people testing positive with a 
new persistent cough 
appeared to be increased 






















transmission in 41 
countries during 
the first wave of the 
pandemic 
• Some interventions 
were more 
effective than 










• Authors caution 




not be seen as final 
but contribute to 


















• Several antibodies are in 
use or under development to 
treat COVID-19 
• It is important to predict if 
new variants remain 
susceptible to these 
antibody treatments 
• Here a yeast library that 
covers all mutations to the 
SARS-CoV-2 receptor 
binding domain that do not 
strongly disrupt binding to 
the host receptor (ACE2) 
were mapped to see how 
these mutations affected 
binding to three leading anti-
SARS-CoV-2 antibodies 
• Mutations were identified 
that escape antibody 
binding, including a single 
mutation that escapes both 
antibodies in the Regeneron 
antibody cocktail  
• Many of the SARS-CoV-2 
mutations that evade 
antibodies are already 
circulating in the human 
population, including one 
mutation that evades both 













19.02.2021 Effectiveness of 








cohort study of 
5.4 million 
people 
SSRN | preprint 
(not peer 
reviewed) 
• A ‘real-world’ 
prospective cohort 
study to estimate 
the effectiveness of 

















mortality records for 
5.4 million people in 
Scotland 
• The first dose of the 
BNT162b2 vaccine 
was associated with 
85% (95% CI 76 to 
91) drop in risk of 
COVID-19 hospital 
admission at 28-34 
days post-
vaccination 
• The first dose of the 
ChAdOx1 vaccine 
was associated with 
94% (95% CI 73 to 
99) drop in risk of 
COVID-19 hospital 
admission at 28-34 
days post-
vaccination 
• Combined vaccine 




(81%; 95% CI 65 to 






>=80y at 28-34 
days post-
vaccination 





reductions in the 







influence of the 













The Lancet | 
Article 
• Data is from all four 
studies of the three 
single-blind 
randomised 
controlled trials from 
the UK, Brazil and 
South Africa 
• Results of this 
primary analysis of 
two doses of 
ChAdOx1 nCoV-19 
were consistent with 
those seen in the 
interim analysis of 
the trials and 
confirm that the 
vaccine is 
efficacious, with 
results varying by 
dose interval. The 
interim report 




report includes 332 






between doses of 
Oxford vaccine 
results in higher 
efficacy than 6-
week interval with 
first dose offering 
76% protection in 









• In participants who 
received two 
standard doses, 
after the second 
dose, efficacy was 
higher in those with 
a longer time prime-
boost interval 
(vaccine efficacy 
81.3% [95% CI 
60.3-91.2] at >=12 
weeks) than in 
those with a short 
interval (vaccine 
efficacy 55.1% 
[33.0-69.9] at <6 
weeks) 
• A 3-month dose 
interval may have 
advantages over a 
short dose interval 
for roll-out of a 
pandemic vaccine 
to protect the 
largest number of 
individuals in the 
population as early 
as possible when 
supplies are scarce, 
while also improving 
protection after 
receiving a second 
dose 








The Lancet | 
Correspondence 
• A retrospective 




rate reductions in 
9109 vaccine-
eligible healthcare 
workers (HCWs) in 
the Sheba Medical 
Centre, Israel’s 
largest hospital, 
compared to those 
unvaccinated from 
Dec 2020 to Jan 
2021 











and investigation of 
exposed or 
symptomatic HCWs 
• There were 170 
SARS-CoV-2 
infections among 
HCWs between 19 
Dec 2020 and 24 
Jan 2021 of which 
99 (58%) HCWs 
reported symptoms 
(COVID-19 cases) 




rates following first 
dose 
12.02.2021 Safety and 







variant in South 
Africa 
medRxiv | pre-





trial on safety and 
efficacy of 
ChAdOx1-nCoV19 
in 2026 HIV 
uninfected adults 
(18 to <65y) in 
South Africa 
• A two-dose 
regimen of 
ChAdOx1-nCoV19 
did not show 
protection against 
mild-moderate 
Covid-19 due to 
the B.1.351 variant 





















print (not peer 
reviewed) 
• Retrospective 
analysis of data 
originating from the 
Israeli Ministry of 
Health from March 
2020 to February 
2021 on the 
temporal dynamics 













on 20 Dec 2020 
• In mid-January the 
number of COVID-
19 cases and 
hospitalisations 
started to decline, 




• This trend was 




• This pattern was not 
observed in the 
previous lockdown 
• This is early 
evidence for the 
‘real world’ 
effectiveness of a 
national vaccination 
campaign 
Comments, Editorials, Opinions, Blogs, News  
Publication 
date 
Title/URL Journal | Article type 
22.02.2021 What makes new variants of SARS-CoV-2 
concerning is not where they come from, but the 
mutations they contain 
BMJ | Views and Reviews 
22.02.2021 Tanzania’s president admits country has COVID-
19 problem 
AP | News 
20.02.2021 Severe mental illness: reassessing COVID-19 
vaccine priorities 
The Lancet | World Report 
20.02.2021 Covid-19: UK should send vaccines to poorer 
nations now – WTO chief 
BBC | News 
19.02.2021 Jeremy Farrar: Make vaccine available to other 
countries as soon as our most vulnerable people 
have received it 
BMJ | Feature 
19.02.2021 Covid-19 in Africa BMJ | Editorial 
19.02.2021 Can COVID vaccines stop transmission? Scientists 
race to find answers 
Nature | News 
19.02.2021 Can we do for other essential medicines what we 
are doing for the COVID-19 vaccine? 
BMJ Global Health | 
Commentary 
19.02.2021 Delayed second dose of the BNT162b2 vaccine: 
innovation or misguided conjecture? 
The Lancet | 
Correspondence 
19.02.2021 Country readiness for COVID-19 vaccines WHO | Newsroom Feature 
stories 
19.02.2021 G7 backs Gavi’s COVAX Advance Market 
Commitment to boost COVID-19 vaccines in 
world’s poorest countries 
GAVI | News 
19.02.2021 A universal coronavirus vaccine Science | Editorial 
19.02.2021 Deaths in health workers in Africa highlight vaccine 
inequity 
Science | In Depth 
18.02.2021 World’s largest clinical trial for COVID-19 
treatments expand internationally 
University of Oxford | News 
18.02.2021 Rationale to continue approved placebo-controlled 
COVID-19 vaccine trials in LMICs 
The Lancet | 
Correspondence 
18.02.2021 What do we really know about COVID-19’s impact 
on essential health services? 
CGD | Blog 
17.02.2021 Unprotected African health workers die as rich 
countries buy up COVID-19 vaccines 
Science | News 
17.02.2021 Covid-19: World’s first human challenge trials to 
start in UK 
BBC | News 
16.02.2021 Covid-19: Vaccine as good in ‘real world’ as in trial 
in Israel 
BBC | News 
16.02.2021 The coronavirus is here to stay – here’s what that 
means  
Nature | News feature 
   
 
Dashboards & Trackers  









& policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 

















LSTM Stop TB 
Partnership 








  IDA 


































Cell Press Johns Hopkins 
University 



































Institute of Public 
Health 
    






Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv 
and bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
  
Online learning & events 







for health workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during 
the COVID-19 
pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
is the tole of PFM in 
the “new normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 





starting 16 Nov 
  HIFA 
services during (and 
after) the pandemic 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 












Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 




WHO Academy and 
WHO Info mobile 
applications 





Modelling and Policy 









11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 












online brief with Dr 
David Nabarro 














training for the 
coronavirus disease 
outbreak 

































6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 





of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
  
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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